Xenon Pharma: XEN801 Fails To Meet Efficacy Endpoints In Phase 2 Trial

(RTTNews) - Xenon Pharmaceuticals Inc. (XENE) reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, parallel-group study designed to evaluate XEN801 for the treatment of moderate to severe facial acne. The company said the results from the trial showed that XEN801 did not demonstrate a statistically significant difference from vehicle placebo in its primary endpoint of the percent change in total (inflammatory and non-inflammatory) lesion count from baseline to week 12. The results also showed that XEN801 did not demonstrate statistical significance relative to key secondary efficacy endpoints.

Simon Pimstone, Xenon's CEO, said, "Despite the good scientific and preclinical rationale to pursue SCD1 as a novel acne target, the topline clinical results do not support this hypothesis or the continued development of XEN801."